CA
KURA icon

Clearstead Advisors’s Kura Oncology KURA Stock Holding History

Clearstead Advisors’s Portfolio KURA Stock Details KURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$31.5K Buy
+2,867
New +$27.1K ﹤0.01% 1649
2026
Q1 		– Sell
-90
Closed -$936 – 2583
2025
Q4 		$936 Sell
90
-2,358
-96% -$24.7K ﹤0.01% 2232
2025
Q3 		$21.7K Buy
2,448
+2,050
+515% +$14.6K ﹤0.01% 1612
2025
Q2 		$2.3K Buy
+398
New +$2.44K ﹤0.01% 2295

Other funds holding KURA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return

Clearstead Advisors's KURA Position: Q2 2026 in Review

Clearstead Advisors opened a new position in Kura Oncology (KURA) in Q2 2026: 2,867 shares worth $31.5K. The stake represents ﹤0.01% of the portfolio and ranks #1649 among its holdings. This is a return to the name: Clearstead Advisors previously reported a position in KURA as recently as Q4 2025.

Clearstead Advisors first reported a position in KURA in Q2 2025 and has held it in 4 quarters since. 220 funds tracked by Wall St. Rank hold KURA as of Q2 2026.

  • Clearstead Advisors held 2,867 shares of Kura Oncology worth $31.5K as of Q2 2026.
  • Kura Oncology was a new Clearstead Advisors position in Q2 2026.
  • Kura Oncology made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #1649 holding.
  • Clearstead Advisors first reported a position in Kura Oncology in Q2 2025 and has held it in 4 quarters since.
  • 220 funds tracked by Wall St. Rank held Kura Oncology as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.